Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a prospective, non-comparative, open, observational study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Alvesco |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Asthma control day | 12weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Morning peak expiratory flow | 12weeks | |
| asthma exacerbation | 12weeks | |
| The number of Reliever use |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
outpatients
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Handok Pharmaceuticals | Seoul | Seoul | South Korea |
Not provided
| ID | Term |
|---|---|
| D001249 | Asthma |
| ID | Term |
|---|---|
| D001982 | Bronchial Diseases |
| D012140 | Respiratory Tract Diseases |
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 12weeks |
| Asthma symptom score | 12weeks |
| Number of Participants with Adverse Events | 12weeks |
| D012130 |
| Respiratory Hypersensitivity |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |